Elicio Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Elicio Therapeutics R&D Spending Growth & History (ELTX)
Elicio Therapeutics's r&d spending was $24.9M for fiscal 2025.
View full Elicio Therapeutics company overviewElicio Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.9M | −$8.8M | −26.01% |
| 2024 | 2024-12-31 | $33.7M | $9.8M | +41.12% |
| 2023 | 2023-12-31 | $23.8M | $5.7M | +31.74% |
| 2022 | 2022-12-31 | $18.1M | −$30.6M | −62.83% |
| 2021 | 2021-12-31 | $48.7M | $9.7M | +24.94% |
| 2020 | 2020-12-31 | $39.0M | — | — |
Elicio Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.8M | −$195,000 | −2.78% |
| Q1 2026 | 2026-03-31 | $6.8M | −$1.0M | −13.13% |
| Q4 2025 | 2025-12-31 | $5.1M | −$5.6M | −52.56% |
| Q3 2025 | 2025-09-30 | $5.0M | −$2.2M | −30.09% |
| Q2 2025 | 2025-06-30 | $7.0M | −$1.2M | −14.35% |
| Q1 2025 | 2025-03-31 | $7.8M | $219,000 | +2.90% |
| Q4 2024 | 2024-12-31 | $10.7M | $4.6M | +73.93% |
| Q3 2024 | 2024-09-30 | $7.2M | −$56,000 | −0.77% |
| Q2 2024 | 2024-06-30 | $8.2M | $3.2M | +65.45% |
| Q1 2024 | 2024-03-31 | $7.6M | $2.1M | +37.84% |
| Q4 2023 | 2023-12-31 | $6.2M | — | — |
| Q3 2023 | 2023-09-30 | $7.3M | $2.7M | +58.15% |
| Q2 2023 | 2023-06-30 | $4.9M | −$97,000 | −1.92% |
| Q1 2023 | 2023-03-31 | $5.5M | −$6.2M | −53.00% |
| Q3 2022 | 2022-09-30 | $4.6M | −$8.7M | −65.43% |
| Q2 2022 | 2022-06-30 | $5.0M | −$9.4M | −65.10% |
| Q1 2022 | 2022-03-31 | $11.7M | −$2.6M | −18.40% |
| Q4 2021 | 2021-12-31 | $6.7M | −$4.4M | −39.74% |
| Q3 2021 | 2021-09-30 | $13.3M | $7.2M | +118.34% |
| Q2 2021 | 2021-06-30 | $14.4M | $2.2M | +18.10% |
| Q1 2021 | 2021-03-31 | $14.3M | $4.7M | +49.00% |
| Q4 2020 | 2020-12-31 | $11.1M | — | — |
| Q3 2020 | 2020-09-30 | $6.1M | — | — |
| Q2 2020 | 2020-06-30 | $12.2M | — | — |
| Q1 2020 | 2020-03-31 | $9.6M | — | — |
Elicio Therapeutics r&d spending trends
Over the last five fiscal years, Elicio Therapeutics's r&d spending decreased from $39.0M to $24.9M, a change of −$14.1M. The latest reported quarter, Q2 2026, shows $6.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elicio Therapeutics source filings ↗